MRK – Merck & Co., Inc.
Merck & Company, Inc.MRK
$105.26Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $262,916,669,440.00
EPSttm : 7.56
Merck & Company, Inc.
$105.26
0.75%$0.8Float Short %
1.5
Margin Of Safety %
10
Put/Call OI Ratio
0.69
EPS Next Q Diff
-0.81
EPS Last/This Y
1.32
EPS This/Next Y
-0.68
Price
105.29
Target Price
110.52
Analyst Recom
1.96
Performance Q
16.79
Relative Volume
0.55
Beta
0.3
Ticker: MRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-02 | MRK | 101.06 | 0.59 | 0.78 | 739755 |
| 2025-12-03 | MRK | 102.32 | 0.60 | 0.57 | 748445 |
| 2025-12-04 | MRK | 100.89 | 0.61 | 0.75 | 754082 |
| 2025-12-05 | MRK | 99.72 | 0.61 | 0.55 | 760107 |
| 2025-12-08 | MRK | 98.96 | 0.60 | 0.06 | 742619 |
| 2025-12-09 | MRK | 96.86 | 0.60 | 0.96 | 749676 |
| 2025-12-10 | MRK | 97.63 | 0.62 | 0.51 | 767451 |
| 2025-12-11 | MRK | 99.04 | 0.62 | 0.29 | 774678 |
| 2025-12-12 | MRK | 100.31 | 0.62 | 0.02 | 782420 |
| 2025-12-15 | MRK | 100.18 | 0.70 | 0.42 | 712196 |
| 2025-12-16 | MRK | 98.22 | 0.70 | 0.34 | 719014 |
| 2025-12-17 | MRK | 99.35 | 0.70 | 0.48 | 724261 |
| 2025-12-18 | MRK | 100.7 | 0.70 | 0.55 | 728301 |
| 2025-12-19 | MRK | 101.07 | 0.70 | 0.29 | 735837 |
| 2025-12-22 | MRK | 104.72 | 0.63 | 0.42 | 625677 |
| 2025-12-23 | MRK | 105.05 | 0.62 | 0.31 | 638181 |
| 2025-12-26 | MRK | 106.83 | 0.63 | 0.24 | 657927 |
| 2025-12-29 | MRK | 106.65 | 0.63 | 0.54 | 646251 |
| 2025-12-30 | MRK | 106.09 | 0.69 | 0.64 | 627672 |
| 2025-12-31 | MRK | 105.28 | 0.69 | 0.92 | 633978 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-02 | MRK | 101.03 | 18.9 | 4827.7 | 8.97 |
| 2025-12-03 | MRK | 102.27 | 18.9 | 5346.2 | 8.97 |
| 2025-12-04 | MRK | 100.89 | 18.9 | 4683.4 | 8.97 |
| 2025-12-05 | MRK | 99.72 | 18.9 | 4731.4 | 8.97 |
| 2025-12-08 | MRK | 98.93 | 18.9 | - | 8.97 |
| 2025-12-09 | MRK | 96.89 | 18.9 | 4500.0 | 8.97 |
| 2025-12-10 | MRK | 97.62 | 18.9 | 4998.6 | 8.97 |
| 2025-12-11 | MRK | 99.04 | 18.9 | 5177.4 | 8.97 |
| 2025-12-12 | MRK | 100.32 | 18.9 | 5145.5 | 8.97 |
| 2025-12-15 | MRK | 100.26 | 18.9 | 4796.9 | 8.97 |
| 2025-12-16 | MRK | 100.26 | 19.3 | 4295.2 | 8.97 |
| 2025-12-17 | MRK | 99.21 | 19.3 | 5052.1 | 8.97 |
| 2025-12-18 | MRK | 100.71 | 19.5 | 5198.9 | 8.97 |
| 2025-12-19 | MRK | 101.10 | 19.4 | 4911.0 | 8.97 |
| 2025-12-22 | MRK | 104.62 | 19.4 | 5693.8 | 8.97 |
| 2025-12-23 | MRK | 105.15 | 19.4 | 4912.1 | 8.97 |
| 2025-12-26 | MRK | 106.85 | 19.4 | 4554.2 | 8.97 |
| 2025-12-29 | MRK | 106.66 | 19.4 | 4430.6 | 8.97 |
| 2025-12-30 | MRK | 106.08 | 19.4 | 4330.7 | 8.97 |
| 2025-12-31 | MRK | 105.29 | 19.4 | 4273.8 | 8.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-02 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-03 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-04 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-05 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-08 | MRK | -0.63 | -1.22 | 1.11 |
| 2025-12-09 | MRK | -0.63 | -1.22 | 1.11 |
| 2025-12-10 | MRK | -0.63 | -1.22 | 1.29 |
| 2025-12-11 | MRK | -0.63 | -1.22 | 1.29 |
| 2025-12-12 | MRK | -0.63 | -1.22 | 1.29 |
| 2025-12-15 | MRK | -0.63 | -1.23 | 1.29 |
| 2025-12-16 | MRK | -0.63 | -1.23 | 1.29 |
| 2025-12-17 | MRK | -0.63 | -1.23 | 1.29 |
| 2025-12-18 | MRK | -0.63 | -1.23 | 1.29 |
| 2025-12-19 | MRK | -0.63 | -1.23 | 1.29 |
| 2025-12-22 | MRK | -0.63 | -1.32 | 1.29 |
| 2025-12-23 | MRK | -0.63 | -1.32 | 1.29 |
| 2025-12-26 | MRK | -0.63 | -1.32 | 1.50 |
| 2025-12-29 | MRK | -0.63 | -1.31 | 1.50 |
| 2025-12-30 | MRK | -0.63 | -1.31 | 1.50 |
| 2025-12-31 | MRK | -0.63 | -1.31 | 1.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.58
Avg. EPS Est. Current Quarter
2.05
Avg. EPS Est. Next Quarter
1.77
Insider Transactions
-0.63
Institutional Transactions
-1.31
Beta
0.3
Average Sales Estimate Current Quarter
16185
Average Sales Estimate Next Quarter
15990
Fair Value
116.14
Quality Score
97
Growth Score
80
Sentiment Score
88
Actual DrawDown %
21.8
Max Drawdown 5-Year %
-43.4
Target Price
110.52
P/E
13.92
Forward P/E
12.58
PEG
1.26
P/S
4.09
P/B
5.05
P/Free Cash Flow
20.02
EPS
7.56
Average EPS Est. Cur. Y
8.97
EPS Next Y. (Est.)
8.3
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
29.79
Relative Volume
0.55
Return on Equity vs Sector %
9.4
Return on Equity vs Industry %
-0.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
4273.8
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading